JERSEY, Channel Islands, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Executive Officer, Franz Walt , the Company’s President of R&D and Manufacturing, Ed Farrell , and the Company’s Chief
JERSEY, Channel Islands, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 13,800,000 ordinary shares at a price to the public of $7.00 per
JERSEY, Channel Islands , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 12,000,000 ordinary shares at a price to the public of $7.00 per
JERSEY, Channel Islands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the
Positive results from the initial Serological Disease Screening microarray US field trial Positive Verification and Validation data for expanded Immunohematology microarray An additional three Hypercare launch sites initiated in 2019 Successful ISO 13485 : 2016 audit of MosaiQ microarray
JERSEY, Channel Islands , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced positive preliminary US field trial data on the Initial Serological Disease Screening (SDS) Microarray. “We are very encouraged by these results.
JERSEY, Channel Islands , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2019, will be released before market open on Monday, November 4, 2019.
Successful Extended Immunohematology Verification and Validation data paving the way for field trials Positive customer feedback and three additional hypercare sites initiated Preliminary quarterly revenue higher than guided JERSEY, Channel Islands , Oct.
First European hypercare launch site initiated following CE mark approval Initial Serological Disease Screening microarray submitted for CE marking U.S. field trial activities for initial Serological Disease Screening commenced 13 blood grouping reagents approved by the FDA for use with OEM
JERSEY, Channel Islands , July 22, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2019, will be released before market open on Monday, August 5, 2019.
